Lifeline Biotechnologies Inc (LLBO)

[pearsby09]

“Wearable device companies are looking at all of the critical imperatives for health and wellness – activity level, sleep, nutrition – and the connection to chronic disease (diabetes, heart disease, obesity, and more) that impact global populations,” said Antoniacci. “But the iTBra and this technology amplify that notion to a whole different level. On the business side of things, that excites me tremendously!”
Cyrcadia is initially targeting the 40% of women who have dense breast tissue. Twenty-eight states now mandate that physicians tell their patients that they have a dense breast condition, therefore a higher propensity for cancer, and that the current diagnostic modalities are challenged with their condition in which the tissue itself can mask cancer cells and lesions. Additionally, Cyrcadia intends to be a supplementary screening solution for those 70 percent of the population that undergo biopsies on non-cancerous tissue resulting from mammographic referral, representing over 1.2 million biopsies for women on non-cancerous tissue annually.
“It is an honor and privilege to participate in the growth of a product that is truly the only life-changing wearable for women of its kind,” said Antoniacci. “Together, we can positively affect countless women and change the trajectory of my own personal and familial experiences. The ability to help lead that movement is something very special to me.”